{"number":"US12697329B2","kindCode":"B2","documentType":"grant","title":{"original":"Method for reducing side effects from administration of phosphodiesterase-4 inhibitors","english":"Method for reducing side effects from administration of phosphodiesterase-4 inhibitors"},"abstract":{"original":"A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.","english":"A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance."},"applicants":["ARCUTIS BIOTHERAPEUTICS, INC."],"inventors":["David W. Osborne"],"filingDate":"2024-06-17","publicationDate":"2026-08-04","grantDate":"2026-08-04","verifiedWithOffice":true,"pdfUrl":"https://downloadpatent.com/pdf/US12697329B2.pdf","pages":{"en":"https://downloadpatent.com/patent/US12697329B2","zh-Hant":"https://downloadpatent.com/zh-Hant/patent/US12697329B2","ja":"https://downloadpatent.com/ja/patent/US12697329B2"}}